What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study-Reference-Cited by-同舟云学术

What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study

Published:2023-02-15 Issue:3 Volume:46 Page:243-255
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Roldan Munoz Sonia^ORCID,Postmus Douwe^ORCID,de Vries Sieta T.^ORCID,Gross-Martirosyan Liana^ORCID,Bahri Priya,Hillege Hans^ORCID,Mol Peter G. M.^ORCID

Funder

Horizon 2020

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

https://link.springer.com/content/pdf/10.1007/s40264-022-01270-4.pdf

Reference64 articles.

1. European Medicines Agency. European Medicines Agency recommends authorisation of novel treatment for type 2 diabetes. SGLT2 transporter protein inhibitor improves glycaemic control in adult patients with type 2 diabetes mellitus. 2012. https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-authorisation-novel-treatment-type-2-diabetes. Accessed 08 Jun 2022.

2. Barbarawi M, et al. SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis. Heart Fail Rev. 2021. https://doi.org/10.1007/s10741-021-10083-z.

3. Van Baar MJB, et al. SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management. Diabetes Care. 2018;41(8):1543–56. https://doi.org/10.2337/dc18-0588.

4. Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf. 2019;18(4):295–311. https://doi.org/10.1080/14740338.2019.1602116.

5. Bhasale A, Mintzes B, Sarpatwari A. Communicating emerging risks of SGLT2 inhibitors-timeliness and transparency of medicine regulators. BMJ. 2020;369: m1107. https://doi.org/10.1136/bmj.m1107.